Customer-informed enhancements improve comfort, connectivity, performance and everyday usability throughout the Barletta family of boats.

BRISTOL, Ind., Sept. 10, 2026 (GLOBE NEWSWIRE) — Barletta Boats today announced its model year 2027 lineup, introducing a broad series of product updates across the entire product family including Reserve, Lusso, Cabrio, Aria and Sanza series. The MY2027 lineup features redesigned interiors, new color palettes, enhanced helm technology, expanded power offerings, upgraded boarding and docking features and thoughtful refinements designed to elevate the ownership experience while preserving the performance, comfort and craftsmanship that define the Barletta brand.

Available now through Barletta’s dealer network, the MY2027 portfolio reflects extensive customer and dealer feedback, with updates focused on usability, premium fit and finish, connectivity and on-water confidence. Across the lineup, Barletta is introducing new interior color combinations, alpine gray flooring, integrated wireless charging, refined gate-stop designs and additional convenience features that improve everyday boating experiences.

“Our approach for MY2027 was centered on purposeful evolution,” said Josiah Druckenmiller, vice president of design and product development for Barletta. “Every update was evaluated through the lens of how owners actually use their boats. From refinements in materials and color palettes to new helm technologies, docking enhancements and connectivity features, these changes are designed to make the experience on board more intuitive, more comfortable and more enjoyable day after day.”

Several of the most significant enhancements arrive in Barletta’s Reserve, Lusso and Cabrio series. New driftwood dune and gunmetal graphite furniture options replace previous colorways, adding depth and sophistication to the furniture while bringing a more modern aesthetic that pairs with a wider range of finishes. The new alpine gray flooring also adds to a more durable, cohesive appearance. The new Apex Silver rail skin option is available on all models along with integrated wireless charging, mid-ship cleats and a recessed in-floor gate stop design that improves walkability throughout the boat.

For technology-focused boaters, Barletta has expanded digital helm capabilities. Lusso models receive a new Spyder digital control system paired with a 12-inch Simrad display, delivering integrated digital switching and enhanced helm functionality. Cabrio introduces Medallion displays with Spyder digital controls and an available Simrad NSX upgrade option, creating a more intuitive and connected helm experience. In the Cabrio line, the enhanced technology is part of a redesigned helm that features a more open layout, clean lines that is intuitive, modern and refined while giving owners a highly functional driving experience.

Performance-minded customers will find additional options in the MY2027 lineup including the Cabrio line, which adds a 300-horsepower Mercury Verado option across its 24-foot models, providing customers with additional performance capability while maintaining accessibility within the lineup.

Barletta’s value-oriented Aria and Sanza series also receive significant updates for the new model year. Aria features redesigned furniture with integrated grab-handle cutouts, standard Lillipad boarding ladders, a standard Eagle 5 chartplotter and new Silver Smoke and Driftwood Dune interior options. Sanza adds JBL Auracast Bluetooth connectivity, new furniture colors and two new floorplans: the Sanza 20QC and Sanza 22UC.

“Our dealers and customers expect Barletta to continually improve every boat we build, and that’s exactly what this model year represents,” said Matt Thompson, vice president of sales for Barletta. “The MY2027 lineup gives our dealer partners fresh products, meaningful innovations and expanded model choices while staying true to the quality, customer experience and attention to detail that have fueled Barletta’s growth.”

Looking ahead, Barletta will expand its portfolio in October with the introduction of the all-new Halcyon series. Evolving from the Corsa platform, Halcyon is designed for boaters who value distinctive styling, confident performance and a premium on-water experience. Positioned to attract customers seeking a bold expression of the Barletta brand, the new series will further strengthen the company’s lineup while opening the door to a broader range of boating lifestyles. Additional details will be shared at launch.

The MY2027 lineup is available now at authorized Barletta dealerships this fall. Explore the full list of product updates at https://www.barlettapontoonboats.com/new-for-2027

About Barletta Boats
Barletta Boats is a premium marine manufacturer founded in 2017 with a focus on high-quality, innovative products, unrivaled customer experience and strong dealer relationships. Headquartered in Bristol, Ind., Barletta Boats is the fastest-growing company in the pontoon segment with an expansive network of dealer partners across the United States and Canada. The Barletta Boat lineup includes the Reserve, Lusso, Corsa, Cabrio, Aria and Sanza series. Visit www.barlettapontoonboats.com for more information. Barletta Pontoon Boats is a wholly owned subsidiary of Winnebago Industries (NYSE: WGO), a manufacturer of premium outdoor recreation products. For more information visit www.winnebagoind.com.

Media Contact: Daniel Sullivan media@winnebagoind.com

Everest Group’s Customer Experience Management (CXM) Services PEAK Matrix® 2026 recognizes Concentrix as a Leader on the matrix across all three regions, with growth in vision and capability across every geography

NEWARK, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) — Concentrix Corporation (NASDAQ: CNXC), a global technology and services leader, today announced that Everest Group has positioned the company as a Leader in its Customer Experience Management (CXM) Services PEAK Matrix® 2026, placing it highest on the vision axis across all regions. Of 63 CXM service providers assessed, Concentrix was one of only two to achieve a Leader ranking in all three regions: Americas, APAC, and EMEA.

This accomplishment reflects the company’s ability to design, build, and run integrated technology and people operations inside the world’s most complex enterprises; turning ambition into operational reality. Concentrix clients highlighted the company’s relationship management, innovation and analytics capabilities, responsiveness, proactive support, domain expertise, commercial flexibility, and operational delivery as key strengths.

Everest Group awarded Concentrix the highest possible scores in its EMEA report across the critical categories of portfolio mix, vision and strategy, and scope of services. In both the Americas and APAC, Concentrix retained and strengthened its position on the vision and capability axis, despite increased competition in both markets.

The results of the Everest Group report and Concentrix client outcomes demonstrate that the company’s proprietary iX Suite, including its autonomous capabilities, Agentic Operating Framework (AOF), and Forward Deployed Engineering (FDE), are delivering measurable results and enabling clients to bring together people, technology, and operations into a single, coherent model.

Concentrix helps clients achieve measurable business outcomes, and recently delivered a 53% increase in sales conversion rates through Gen AI-powered advisor assistance, a 56% increase in revenue per chat through AI-driven sales training, and a 20X increase in monthly revenue through a transformed customer success operating model.

“Enterprises need technology that works at scale, inside their real-world operations,” said Chris Caldwell, President and CEO of Concentrix. “We bring together the people, technology, and intelligence, orchestrating human expertise and AI, to create experiences and outcomes that matter. Clients trust us with their customers, and that trust is what makes the difference between a strategy on paper and one that delivers. We’re proud that Everest Group continues to recognize both our vision and our proven ability to execute it.”

Everest Group’s Customer Experience Management (CXM) Services PEAK Matrix® 2026 report reflects a central challenge facing every enterprise today: incorporating new technology into business and operations requires operating model redesign. Everest Group identified the combination of consulting-led transformation, proven production-ready technology, and outcome accountability as the critical factors that accelerate value realization for buyers and found that growth in CXM is no longer driven by contact volumes, but by complexity, technology, and outcomes.

The recognition marks the eleventh consecutive time Concentrix has earned Leader positioning on the annual Everest Group CXM PEAK Matrix®. This year’s report evaluated providers across operational services, value-added services, CX consulting and process optimization, and technology, reflecting the full scope of what enterprise clients need as they operationalize AI at scale.

For more information on Concentrix’ CXM services, visit www.concentrix.com.

About us: Powering a World That Works
Concentrix (NASDAQ: CNXC), is the Fortune 500® technology and services company, helping the world’s best brands create intelligent operations that perform in the real world. We design, build, and run integrated human and AI solutions, harnessing the insight from billions of real-world interactions to help 2000+ of the world’s most complex organizations solve their toughest business challenges. Backed by 20+ years of operational experience and battle tested AI, we’re the intelligent transformation partner that helps clients across every major industry move from ambition to measurable, scalable performance. Virtually everywhere. Visit concentrix.com to learn more. 

Media Contact:
Marketing & Communications
Concentrix Corporation
media@concentrix.com

From Fortune. ©2026 Fortune Media (USA) Corporation. All rights reserved. Used under license. Fortune and Fortune 500 are registered trademarks of Fortune Media (USA) Corporation and are used under license. Fortune and Fortune Media (USA) Corporation are not affiliated with, and do not endorse products or services of, Concentrix.

Safe Harbor Statement
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, but are not limited to, statements regarding the company’s capabilities and positioning to deliver business outcomes and solve challenges for its clients, and statements that include words such as believe, expect, may, will, provide, could and should and other similar expressions. These forward-looking statements are inherently uncertain and involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, risks related to the company’s ability to successfully execute its strategy, competitive conditions in the company’s industry, and other factors contained in the Company’s Annual Report on Form 10-K for the fiscal year ended November 30, 2025 filed with the Securities and Exchange Commission and subsequent SEC filings. We do not undertake a duty to update forward-looking statements, which speak only as of the date on which they are made.

Copyright 2026 Concentrix Corporation and its subsidiaries. All rights reserved. Concentrix, the Concentrix logo, and all other Concentrix company, product and services names and slogans are trademarks or registered trademarks of Concentrix Corporation and its subsidiaries.

FALLS CHURCH, Va., Sept. 10, 2026 (GLOBE NEWSWIRE) — Northrop Grumman Corporation (NYSE: NOC) will participate in the 14th Annual Morgan Stanley Laguna Conference on Thursday, September 17. Kathy Warden, chair, chief executive officer and president, will present beginning at 12:15 p.m. Eastern time. The presentation will be webcast live at http://investor.northropgrumman.com.

Northrop Grumman is a leading global aerospace and defense technology company. Our pioneering solutions equip our customers with the capabilities they need to connect and protect the world, and push the boundaries of human exploration across the universe. Driven by a shared purpose to solve our customers’ toughest problems, our employees define possible every day.

Note: Statements to be made at the conference, including in the presentation and in any accompanying materials, contain or may contain statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “will,” “expect,” “anticipate,” “intend,” “may,” “could,” “should,” “plan,” “strategy,” “project,” “forecast,” “achieve,” “believe,” “estimate,” “guidance,” “outlook,” “trends,” “goals,” “confident,” “on track” and similar expressions generally identify these forward-looking statements. These forward-looking statements speak only as of the date when made, and the Company undertakes no obligation to publicly update or revise any forward-looking statements after the date of the conference, except as required by applicable law. Forward-looking statements are not guarantees of future performance and inherently involve a wide range of risks and uncertainties that are difficult to predict. A discussion of these risks and uncertainties is contained in the Company’s filings with the Securities and Exchange Commission.

Contact: News Bureau
newsbureau@ngc.com

Randy Sinclair (Investors)
randy.sinclair@ngc.com

DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE), a leading global contract research organization (“CRO”), today announced that CEO Anshul Thakral, CFO Jason Knoblauch, and SVP of Investor Relations, Tracy Krumme will participate in the following conferences in September:

Baird 2026 Global Healthcare Conference (NYC)

Date: Tuesday, September 15, 2026
Format: Fireside Chat & 1×1 and Group Meetings
Time: 2:00 -2:30 PM EDT
Webcast: FTRE Baird Webcast

Deutsche Bank 2026 Healthcare Summit (NYC)

Date: Wednesday, September 16, 2026
Format: 1×1 and Group Meetings

RBC Pharma Services and Life Science Tools Virtual Conference

Date: Tuesday, September 22, 2026
Format: 1×1 and Group Meetings

The live webcast and replay of the Baird fireside chat will be accessible through the “Events” section of Fortrea’s Investor Relations website. Investors interested in meeting with management should contact their banking representatives.

About Fortrea

Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in 100 countries is scaled to deliver focused and agile solutions to clients globally. Learn more about how Fortrea is streamlining drug development at Fortrea.com and follow us on LinkedIn, X and Bluesky.

Fortrea Contacts

Tracy Krumme (Investors) – 984-385-6707, tracy.krumme@fortrea.com
Sue Zaranek (Media) – 919-943-5422, media@fortrea.com
Kate Dillon (Media) – 646-818-9115, kdillon@prosek.com

SAN DIEGO, Sept. 10, 2026 (GLOBE NEWSWIRE) — LPL Financial LLC announced today that financial advisor Jeneen Slack, CFP®, CDFA®, founder and partner of Northstar Financial Advisors, LLC, has joined LPL Financial’s broker-dealer and Registered Investment Advisor (RIA) platform. Slack reported serving more than $270 million in client assets* and joins LPL from Raymond James.

With nearly 20 years of industry experience, Slack built her practice on a belief that financial advice is most impactful when it is rooted in strong personal relationships. Initially inspired by a desire to help women feel more confident discussing and managing their finances, her approach today is centered on helping individuals and families make informed decisions about their financial futures.

Based in Danville, Calif., Slack serves a diverse clientele throughout the Bay Area, including professionals, families, retirees and individuals navigating major life transitions. As a Certified Divorce Financial Analyst (CDFA®), she specializes in helping clients understand the financial implications of divorce and supporting their long-term planning needs beyond the process itself.

“Relationships are truly at the heart of everything we do at Northstar,” Slack said. “We’ve intentionally built a personalized service model where every member of our team knows our clients personally and understands what matters most to them. Whether we’re helping someone navigate retirement, prepare a child for financial independence or make complex decisions during a divorce, our goal is to provide guidance that evolves alongside our clients’ lives.”

Slack, along with her business partner and fellow financial advisor Eric Slack, is supported by Kari Jeha, Jon Lee and V. John Threlkeld. Together, they bring decades of combined industry experience and a hands-on approach focused on delivering individualized service. Beyond working with clients, the practice is deeply committed to community engagement – regularly hosting educational workshops, retirement planning programs and client events designed to foster deeper connections and financial literacy.

Why Northstar Financial Advisors Chose LPL

As she looked ahead to the next chapter of her career, Slack sought a partner that would give her the flexibility to build Northstar around her vision for the future while providing the scale and resources of a leading financial services firm. She was particularly attracted to LPL’s commitment to innovation, its advanced technology capabilities and the depth of support available to established advisors.

“I’m at a point in my career where I wanted a partner that is continually investing in the future of advice,” Slack said. “LPL gives us the flexibility and resources to operate the way we believe is best for our clients, while providing the technology and support to help our team work more efficiently. That combination allows us to focus on what matters most — delivering thoughtful, personalized guidance and maintaining the strong relationships we’ve built with our clients.”

Marc Cohen, Chief Growth Officer at LPL Financial, said, “What Jeneen has built at Northstar is personal by design. She and her team take the time to know their clients, helping women engage more confidently with their finances and guiding individuals and families through the decisions and transitions that shape their lives. We are honored that Jeneen chose LPL for Northstar’s next chapter and look forward to helping the team extend that experience to more clients.”

Related

Advisors, learn how LPL Financial can help take your business to the next level.

About LPL Financial

LPL Financial Holdings Inc. (Nasdaq: LPLA) is among the fastest growing wealth management firms in the U.S. As a leader in the financial advisor-mediated marketplace, LPL supports more than 32,000 financial advisors and the wealth management practices of approximately 1,100 financial institutions, servicing and custodying approximately $2.6 trillion in brokerage and advisory assets on behalf of approximately 8 million Americans. The firm provides a wide range of advisor affiliation models, investment solutions, fintech tools and practice management services, ensuring that advisors and institutions have the flexibility to choose the business model, services, and technology resources they need to run thriving businesses. For further information about LPL, please visit www.lpl.com.

Securities and advisory services offered through LPL Financial LLC (“LPL Financial”), a registered investment advisor and broker-dealer, member FINRA/SIPC. Northstar Financial Advisors and LPL Financial are separate entities.

LPL Financial does not offer tax advice or tax preparation services.

Throughout this communication, the terms “financial advisors” and “advisors” are used to refer to registered representatives and/or investment advisor representatives affiliated with LPL Financial.

We routinely disclose information that may be important to shareholders in the “Investor Relations” or “Press Releases” section of our website.

*Value approximated based on asset and holding details provided to LPL from end of year, 2025.

Media Contact: 
Media.relations@LPLFinancial.com  

Tracking #1171024

Health Canada-authorized trial to evaluate a single supervised dose of natural psilocybin, with dosing expected to be completed by the end of 2027

Up to 200 participants at sites across Canada, among the largest studies of naturally derived psilocybin to date

VANCOUVER, British Columbia, Sept. 10, 2026 (GLOBE NEWSWIRE) — Optimi Health Corp. (Nasdaq: OPTH) (“Optimi” or the “Company”), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, announces plans to initiate a multisite Phase 2 clinical trial evaluating psilocybin-assisted therapy for individuals with major depressive disorder (“MDD“). The trial is planned to be initiated in the first half of 2027, with dosing expected to be complete by the end of 2027.

The Phase 2 clinical trial is authorized to proceed by Health Canada and will enroll up to 200 participants across multiple sites in Canada, evaluating the safety and efficacy of a single supervised dose of natural psilocybin in the treatment of MDD. The primary efficacy endpoint is the change in Montgomery-Åsberg Depression Rating Scale (MADRS) total score from baseline, the most widely used clinician-rated measure of depressive symptom severity in trials of this kind.

“A 200-subject Phase 2 trial in major depressive disorder is the largest clinical commitment Optimi has made to date. We will supply our own naturally derived psilocybin, manufactured at our GMP facility, and we will have exclusive ownership of the trial results,” said Dane Stevens, Optimi Chief Executive Officer and Co-Founder. “As we broaden our strategy to include clinical drug development, this Phase 2 trial is an initial step toward potential registration. Few companies in this sector are commercial today while also advancing their own clinical development. In Canada, we already hold a Drug Establishment Licence and supply psilocybin through Health Canada’s Special Access Program. This trial builds directly on that foundation, and we can comfortably fund it with current cash on hand.”

The clinical trial is set to be one of the largest clinical studies of naturally derived psilocybin to date, and will include periodic interim safety and efficacy readouts, with full topline results available after dosing and follow-up evaluations are completed for all 200 participants.

MDD is among the most common mental health conditions worldwide, affecting an estimated 332 million people, according to the World Health Organization.1 A substantial proportion of patients do not respond adequately to existing antidepressant treatments, which typically require weeks of continuous use before clinical benefits emerge.

1World Health Organization, Depressive disorder (depression) fact sheet, 2025. Available at: https://www.who.int/news-room/fact-sheets/detail/depression

The safety and efficacy of psilocybin assisted therapy to treat MDD is still under investigation and none of Optimi’s psilocybin drug products received market authorization by Health Canada.

About Optimi Health Corp.

Optimi Health Corp. is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, Optimi produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada. Optimi supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products currently prescribed to patients in Australia under the country’s Authorized Prescriber Scheme and accessible in Canada through the Special Access Program.

For more information, please visit optimi.net.

For more information, please contact:
Dane Stevens, CEO
Optimi Health Corp.
(778) 761-4551
investors@optimihealth.ca
www.optimihealth.ca

Investor Relations Contact:
CORE IR
ir@optimi.net

Forward-Looking Statements

This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws, including statements regarding the proposed clinical trial, the availability and enrolment of patients in the trial, the utilization of the data derived from the trial, and the ability to conduct evaluations as part of the trial, the Company’s ability to manufacture and ship products from its Canadian facility, and the Company’s positioning in the regulated psychedelic medicine market. Forward-looking statements and forward-looking information are often identified by words such as “expects,” “anticipates,” “believes,” “intends,” “plans,” “estimates,” “may,” “will,” “would,” “could,” or similar expressions. Forward-looking statements and forward-looking information are based on several assumptions and are subject to a number of known and unknown risks and uncertainties, many of which are beyond the Company’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Accordingly, there are or will be important factors that may cause actual results to differ from expected results. These factors include those described under “Risk Factors” in the Company’s registration statement on Form F-1, as amended, and other filings with the U.S. Securities and Exchange Commission made from time to time which are available at www.sec.gov and on SEDAR+ at www.sedarplus.ca and in the Company’s continuous disclosure filings available under its SEDAR+ profile at www.sedarplus.ca. These forward-looking statements reflect current expectations of management regarding future events and speak only as of the date of this press release. Except as expressly required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for the Company to predict all of them or assess the impact of each factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement.

Neither the Canadian Securities Exchange nor the Canadian Investment Regulatory Organization accepts responsibility for the adequacy or accuracy of this release.

VANCOUVER, British Columbia, Sept. 10, 2026 (GLOBE NEWSWIRE) — Cannabix Technologies Inc. (the “Company or Cannabix”) developer of marijuana and alcohol breath testing technologies, is pleased to announce the deployment of its BreathLogix alcohol monitoring solution with the Lake County Community Corrections Program in Indiana. Lake County is Indiana’s second-most populous county, serving residents in the greater Chicago metropolitan region.

The BreathLogix system will support court-ordered alcohol monitoring initiatives administered by Lake County’s community corrections program staff. The deployment is designed to assist program administrators in monitoring participant compliance with court-imposed abstinence requirements while improving operational efficiency and reducing administrative burden.

Under the program, participants are required to undergo scheduled or random alcohol testing as a condition of probation, treatment, pre-trial release, or other court-supervised programs. The deployment is being facilitated by AlcoPro, Inc., an authorized reseller.

Under the program, participants may be required to undergo scheduled or random alcohol testing as a condition of probation, diversion, treatment, pre-trial release, or other court-supervised programs. BreathLogix enables participants to provide breath samples autonomously while maintaining identity verification through integrated photo capture technology.

BreathLogix rapidly screens for alcohol using a breath sample while simultaneously capturing a photograph of the user for identity verification. The system provides precise Blood Alcohol Content (BAC / BrAC) readings and can automatically deliver real-time alerts via SMS and email to designated program administrators when positive results are detected.

The deployment further expands Cannabix’s presence within the U.S. corrections, probation, treatment, and public safety markets where organizations are seeking automated alcohol testing solutions that improve compliance oversight while reducing staffing requirements.

BreathLogix Alcohol device available with for County Sobriety Programs

Figure 1. BreathLogix Alcohol device available with for County Sobriety Programs

BreathLogix supports a broad range of alcohol monitoring applications, including:

  • Court-ordered alcohol monitoring
  • Probation and parole programs
  • Pre-trial release supervision
  • Diversion and specialty court programs
  • Treatment and recovery programs
  • Random and scheduled alcohol testing
  • Workplace and safety-sensitive screening
  • Return-to-work and fitness-for-duty assessments

By enabling frequent, reliable and automated alcohol screening, BreathLogix helps courts, treatment providers and supervision agencies strengthen compliance monitoring, improve participant accountability and enhance public safety outcomes.

Marketing Agreement

The Company has entered into a marketing services agreement (the “Agreement”) with Outside the Box Capital Inc. (“OTBC”), an arm’s-length marketing firm based in Oakville, Ontario. Pursuant to the Agreement, OTBC will provide marketing services, including social media marketing, content planning and creation, and the production and distribution of feature content regarding the Company through OTBC’s proprietary media channels and selected third-party platforms. The Agreement is effective September 9, 2026, for a term of six months. In consideration for the services to be provided under the Agreement, the Company has agreed to pay OTBC a one-time cash fee of $150,000 plus applicable taxes and 335,000 stock options (the “Options”) to acquire common shares of the Company at an exercise price of $0.45 per share for a period of one year from the date of grant. The Options will vest in accordance with the policies of the Canadian Securities Exchange and the Company’s equity incentive plan. Any common shares issued upon the exercise of the Options will be subject to a statutory hold period of four months and one day from the date of issuance, in accordance with applicable securities laws.

OTBC is controlled by Jason Coles. OTBC and Mr. Coles are arm’s-length parties to the Company. Other than the Options described above, neither OTBC nor Mr. Coles currently holds any direct or indirect interest in the Company or its securities. OTBC has no relationship with the Company other than pursuant to the Agreement described in this news release.

About Cannabix Technologies Inc.

Cannabix Technologies Inc. is a leading developer of breath-based technologies designed to enhance public safety and reduce impairment-related risks in a range of different settings. The Marijuana Breath Test (MBT) targets delta-9 THC—the primary psychoactive compound in cannabis—in breath, providing a practical solution for identifying recent marijuana use.

The BreathLogix, unmanned alcohol screening solution supports organizations in proactively monitoring alcohol impairment, strengthening safety protocols, and promoting responsible behavior. By delivering innovative, non-invasive screening tools, Cannabix aims to help reduce accidents, improve decision-making, and protect organizations, individuals and the public at large. Visit www.cannabixtechnologies.com

We seek Safe Harbor.
On behalf of the Board of Directors

“Rav Mlait”

CEO
Cannabix Technologies Inc.

For further information, contact the Company at info@cannabixtechnologies.com

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward-Looking Statements

This news release contains certain “forward-looking statements” within the meaning of applicable securities laws. Forward-looking statements are often identified by words such as “expects,” “anticipates,” “believes,” “intends,” “plans,” “may,” “will,” “could,” “should,” “potential,” and similar expressions. Forward-looking statements in this news release include, but are not limited to, statements regarding: the anticipated benefits, performance and adoption of the Company’s BreathLogix alcohol monitoring system; the expected use of the system by community corrections agencies and other public sector organizations; the Company’s ability to expand deployments of BreathLogix in the United States and other jurisdictions; the commercialization and market acceptance of the Company’s products and technologies; the Company’s ability to enter into additional customer, distribution, service, or strategic partnership agreements; and the Company’s ongoing business, product development and financing plans. Forward-looking statements are based on management’s current expectations, assumptions and beliefs and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements. Such factors include, without limitation: the ability of the Company to successfully deploy and support its technologies; customer adoption and retention; regulatory developments; changes in government procurement practices or community corrections requirements; competitive developments; technological advancements by competitors; economic and market conditions; the availability of financing; and other risks detailed from time to time in the Company’s public disclosure documents. There can be no assurance that the Company’s products will achieve commercial acceptance, that existing deployments will lead to additional contracts or revenue opportunities, or that any anticipated business objectives, strategic initiatives, partnerships, or growth opportunities will be realized. Actual results may differ materially from those currently anticipated in such forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof and are based on the beliefs, estimates, expectations and opinions of management on the date such statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c280215e-c351-42df-b85c-5f581f46994e

 

Bank of Åland Plc
Stock exchange release
September 10, 2026, 15.45 EEST

Bank of Åland Plc to increase prime rate

The Bank of Åland Plc (Ålandsbanken Abp) has decided to increase its prime rate by 0.25 percentage points, from 2.25 per cent to 2.50 per cent. The basis for this decision is rising market interest rates. The change goes into effect on September 24, 2026.

Bank of Åland Plc

For further information, please contact:
Peter Wiklöf, Managing Director and Chief Executive, Bank of Åland Plc, tel +358 40 512 7505

Company will hold a formal presentation and one-on-one investor meetings September 14-16, 2026

MBody AI

ISFIYA, Israel and LAS VEGAS, Sept. 10, 2026 (GLOBE NEWSWIRE) — MBody AI Ltd. (“MBody AI” or the “Company”) (NASDAQ: MBAI) today announced that John Fowler, Chief Executive Officer and Tim Hayden, Chief Financial Officer of MBody AI, will present at the H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026, at the Lotte New York Palace Hotel in New York City.

In addition to the formal presentation which will be available On-Demand, management will be available for one-on-one investor meetings during the conference. Investors interested in scheduling a one-on-one meeting with management during the conference should contact their H.C. Wainwright representative or meetings@hcwco.com or Lytham Partners at 602-889-9700 or ir@mbody.ai.

MBody AI’s Orchestrator is a proprietary, hardware-agnostic software platform that serves as an intelligence layer designed to enable autonomous systems to operate, coordinate, and improve more effectively than they otherwise would in real-world physical environments. It is designed as a full-stack embodied AI software system that integrates multiple functional components intended to support autonomous operation and fleet-level coordination.

The two core features of Orchestrator are AI Optimization, Task Verification and Reporting. AI Optimization uses artificial intelligence to assess telemetry and run-time data and generate recommendations to improve performance against customer key performance indicators, across a customer’s fleet regardless of brand.

Task Verification and Reporting provides unified dashboarding and reporting across a customer’s full fleet and multiple robot types, including verification that assigned tasks have been completed.

Learn more about MBody AI’s growth trajectory at ir.mbody.ai

About H.C. Wainwright & Co.

H.C. Wainwright & Co., LLC is an investment bank dedicated to providing corporate finance, strategic advisory, sales & trading, research, and related services to public and private growth companies across multiple focuses and regions. The HCW team has been the leader in the CMPO (confidentially marketed public offerings), RD (registered direct offering) and PIPE (private investment in public equity) transaction markets since 1998.

About MBody AI Ltd.

MBody AI Ltd. (NASDAQ: MBAI) develops enterprise software that deploys and manages autonomous robot workforces for hospitality and gaming operators. The Company’s proprietary MBody AI Orchestrator is a hardware-agnostic software platform that manages diverse robot fleets from multiple vendors across sites and use cases under long-term agreements. MBody AI counts Fortune 500 operators among its customers.

No Offer or Solicitation

This press release does not constitute an offer to sell or a solicitation of an offer to buy, and shall not constitute an offer, solicitation, or sale in any state, province, territory, or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements made in graphics, images, headlines, and other visual elements of this release. All statements other than statements of historical fact are forward-looking statements, which include, among others, statements regarding the expected performance, functionality, and capabilities of the MBody AI Orchestrator platform; the Company’s technology roadmap; the Company’s expectation that operational data generated by its deployments will refine its models and improve platform performance over time; the Company’s deployment pipeline, customer expansion, and commercial scaling; the anticipated growth of the embodied AI market; the Company’s ability to maintain continued compliance with Nasdaq listing requirements; and the Company’s continued qualification as a foreign private issuer. These forward-looking statements are based on the Company’s current intentions, beliefs, and expectations regarding future events. Actual results may differ materially due to risks and uncertainties including, but not limited to, the risk that the multi-brand fleet control capability does not complete testing or is not deployed with customers on the anticipated timeline or at all; the risk that the customer-systems integration capability is never completed or made available, and that the related provisional patent applications do not result in issued patents; the risk that the platform does not perform as designed or that operational data does not yield the expected improvements; customer concentration risk, the Company being substantially dependent on two enterprise customers; the Company’s ability to convert pilot deployments into contracted revenue; the risk that the Company fails to satisfy Nasdaq continued listing standards, including the minimum bid price and shareholders’ equity requirements; the risk that the Company ceases to qualify as a foreign private issuer and becomes subject to domestic reporting requirements; the Company’s need for additional capital and the dilutive effect of any financing; market conditions; and other factors described in the Company’s filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update forward-looking statements except as required by law.

Quick Facts

Issuer: MBody AI Ltd. (NASDAQ: MBAI)
Listing: Nasdaq Capital Markets
Sector: Technology
Industry: Embodied AI and enterprise robotics (physical AI)
Event: H.C. Wainwright 28th Annual Global Investment Conference
Date: September 14-16, 2026
Location: Lotte New York Palace Hotel, New York City
CUSIP M6S83C106

Investor Relations:
Lytham Partners, LLC
602-889-9700
ir@mbody.ai

Media Contact:
Core IR
ir@mbody.ai

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1633c2e1-2003-4789-b023-5900f7374b46

DENVER, Sept. 10, 2026 (GLOBE NEWSWIRE) — SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life announced today that Eric Schlorff, Chief Executive Officer of SeaStar Medical, will participate in the upcoming HC Wainwright 28th Annual Global Investment Conference being held September 14 to 16, 2026 in New York City.

The SeaStar Medical presentation will be available on September 11, 2026, at 7:00 am Eastern Time and can be accessed by visiting the Events & Presentations page, located under the Investor Relations section of the SeaStar Medical website. The presentation will be available for 60 days following the event.

About SeaStar Medical

SeaStar Medical is a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life. SeaStar Medical’s first commercial product, QUELIMMUNE (SCD-PED), was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening Acute Kidney Injury (AKI) due to sepsis or a septic condition requiring renal replacement therapy (RRT) in critically ill pediatric patients. SeaStar Medical’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. The company is currently conducting the NEUTRALIZE-AKI pivotal clinical trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy, a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually.

For more information visit www.seastarmedical.com or visit us on LinkedIn or X.

Contact:
IR@SEASTARMED.COM

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.